Skip to main content
AmigoFish

The race for access: How the FAIR Act could reclaim U.S. biotech leadership

From BioSpace · · 20 min

This plays from the publisher's own server. We do not host a copy.

Open at the source

Not rated yet

Description

In this episode of Denatured, you’ll hear from Max Bronstein, CEO of Aviva Strategies and Teresa Barnes, Chief Executive Warrior of PF Warriors. We dig into why U.S. patients are losing access to rare disease trials happening abroad and how the FAIR Act’s accelerated, harmonized reviews could help the U.S. keep pace while getting lifesaving studies to patients faster.

Host

⁠Jennifer C. Smith-Parker (https://www.linkedin.com/in/jennifersmithparker/), Director of Insights, BioSpace

Guests

Max Bronstein (https://www.linkedin.com/in/maxgbronstein/), CEO, Aviva Strategies

Teresa Barnes (https://www.linkedin.com/in/teresa-barnes-85a30814/), Chief Executive Warrior, PF Warriors

Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.

Back to BioSpace · Report a problem